The Patients’ Journey with Targeted Therapies
Oral targeted therapies have become central in the management of advanced cancer since they delay the progression of the disease and extend overall survival of the patients. Targeted therapies, despite inducing some dramatic response, rarely eradicate cancer but rather switch it to a chronic state. This implies that the treatments are taken chronically over several months or years with consequences on compliance. This is of particular importance since these drugs have also specific side effects that can greatly affect patients’ quality of life. In the present chapter, the main side effects of targeted therapies, their management from the angle of specialised nursing care, and several prophylactic measures have been reviewed. The nurse indeed plays a critical role in guiding and supporting patients receiving oral treatments. A multidisciplinary and multi-professional approach involving physicians, pharmacists, and paramedical staff guarantees a better efficiency. In addition, properly educated patients will improve their adherence to treatment.
KeywordsTargeted cancer therapy Treatment adherence Therapeutic education Side effects Guidelines Quality of life
- 1.Adherence to long-term therapies: evidence for action. Available from www.who.int/chp/knowledge/publications/adherence_full_report.pdf
- 2.Mikael D. Chimiothérapie orales: Mythes et réalités, centre Henri Bequerel, Rouen. 2010. https://onconormandie.fr/wp-content/uploads/2017/05/Chimiotherapie-orale-adherence-M.Daouphars.pdf
- 4.National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Available from http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed 16 Mar 2009.
- 5.Targeted Therapy, American Society of Cancer. Available from https://www.cancer.org/treatment/targeted-therapy.htlm
- 8.Lacouture ME, Tsao AS, Oishi K. Strategies for rash management: an expert-guided discussion for nurses. ONS Connect. 2010;25:47–8.Google Scholar
- 14.Mario E, Lacouture ME. The growing importance of skin toxicity in EGFR inhibitor therapy. Oncology (Williston Park). 2009;23(2):194–6.Google Scholar
- 27.BCCA guidelines for management of chemotherapy-induced diarrhea. Available from www.bccancer.bc.ca/nursing-site/Documents/GuidelinesforManagementofCDI.pdf
- 29.Lim SL, Ang E. Validity and reliability of nutrition screening administered by nurses. Sage Journals. First published October 9, 2013.Google Scholar
- 34.Horne R. Compliance, adherence and concordance. In: Taylor KMG, Harding G, editors. Pharmacy practice. London: Taylor & Francis; 2001.Google Scholar
- 35.NICE Medicines Adherence guidelines. 2009. Available from https://www.nice.org.uk/guidance/cg76/evidence/full-guideline-242062957
- 38.MASCC Oral Agent Teaching Tool (MOATT). Available from www.mascc.org/assets/documents/moatt_userguide.pdf
- 39.NCCN Distress thermometer and problem list for patients. Available from https://www.nccn.org/patients/resources/life_with_cancer/pdf/nccn_distress_thermometer.pdf